Serta Simmons Bedding just announced that they are going to create a mattress that kills COVID-19 with a 99.9% effective rate.
The company is partnering with HeiQ Group, a Switzerland-based company that is known for being a leader in textile innovation to develop the world’s first antiviral mattress.
How the antiviral mattress works
The agreement gives Serta the exclusive rights to use HeiQ Viroblock technology, which already has approval from the European Medical Device Directive for use in protective antiviral equipment for medical workers, such as N95 masks. Independent tests from an Australian infection and immunity research institute show that HeiQ Viroblock technology has already been rated as being 99.9% effective in 30 minutes against COVID-19.
Virus particles are – obviously – invisible to the human eye. Since they are only 90 nanometers large, they can easily pass through sheets and bedding. Research is still ongoing, but current thinking indicates that the virus can stay active and infectious on textiles – such as mattresses – for days.
HeiQ Viroblock uses mirosilver technology to attract the virus particles, which combine with vesicle technology to to break down the viral membrane in a matter of seconds. The Peter Doherty Institute for Infection and Immunity conducted tests that showed that coronavirus samples on fabric treated with HeiQ Viroblock were reduced by 99.9%.
Serta Simmons Bedding is planning to pursue FDA and EPA approval for their Serta and Beautyrest HeiQ Viroblock mattresses. If they gain approval, they will utilize the HeiQ Viroblock technology across their suite of products including Serta, Tuft & Needle, and Beautyrest.
“We know that our partners in the hospitality and healthcare industries are doing everything they can to help provide the cleanest environment and reassure their guests,” said CEO David Swift, who is also the chairman of Serta Simmons Bedding. “Antiviral and antibacterial mattresses will be an enormous asset in that effort.”